☰

Test helps target glioblastoma patients most likely to benefit from bevacizumab




A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin), according to new research from the University of Texas MD Anderson Cancer Center.

Fuente : http://www.eurekalert.org/pub_releases/2013-06/uot...

Domingo, 2 de Junio 2013
Jueves, 1 de Enero 1970
1

1 1
Otros artículos de esta sección